摘要:
Compounds are provided which are inhibitors of the CAXII enzyme. Due to the interaction between CAXII and Pgp, such compounds may be useful in lowering the chemoresistance of a cancer allowing for co-administration with existing anti-cancer agents.
摘要:
The application describes small molecules capable of modulating activity of beta2 family of integrins, such as integrin CD11b/CD18 (also known as Mac-1, CR3 and αΜβ2). Such compounds may be used in certain embodiments for treating a disease or condition, such as inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, wound-healing, organ transplantation and cardiovascular disease, among others.
摘要:
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.
摘要:
A compound, or a pharmaceutically acceptable salt thereof, having a structure of: Formula A wherein A is a ring; Y 1 and Y 2 are each independently N or C with the proper valency; X 1 and X 2 are each independently -NH-, -0-, -CH 2 -0-, -NH-CH 2 -, or -N(CH 3 )-CH 2 -, provided that when at least one of X 1 and X 2 is -CH 2 -0-, -NH-CH 2 -, or -N(CH 3 )-CH 2 - then the - CH 2 - is directly connected to A; a and b are each independently 0 or 1; c and d are each independently 0 or 1; Z 1 and Z 2 are each independently a heterocyclic; and R 1 and R 2 are each independently optionally substituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, amino, optionally substituted heteroaralkyl, optionally substituted alkylalkoxy, optionally substituted alkylaryloxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; provided that if Y 1 and Y 2 are each C, then a is 1 and b is 1; provided that if Y 1 and Y 2 are each N, then a is 0 and b is 0; provided that if Y 1 is N and Y 2 is C, then a=0 and b=l; provided that if Y 1 is C and Y 2 is N, then a=l and b=0; provided that if c=0 and d=0, then R 1 and R 2 are both amino; provided that if c is 1 and d is 1, then both R 1 and R 2 are not amino; provided that if c is 0 and d is 1, then R 1 is amino and R 2 is optionally substituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroaralkyl, optionally substituted alkylalkoxy, optionally substituted alkylaryloxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; and provided that if c is 1 and d is 0, then R 2 is amino and R 1 is optionally substituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroaralkyl, optionally substituted alkylalkoxy, optionally substituted alkylaryloxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl.
摘要:
The present disclosure provides compounds of formula (I) to (III) as glutaminase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders involving glutamine.
摘要:
Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.
摘要:
The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N- [3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula(I) as described and defined herein,to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.
摘要:
The invention relates to compounds and pharmaceutical compositions useful in combination with tetracyclines in the treatment of bacterial infections caused by Gram- positive and Gram-negative pathogens, with particular efficacy in tetracycline resistant strains. These compounds specifically bind to TetR and therefore prevent the transcriptional activation of tet resistance genes. The compounds have a potentiating effect on the activity of members of the tetracycline family, in particular of tetracycline, minocycline, doxycycline and tigecycline, in the treatment of tetracycline susceptible, intermediate and tetracycline resistant pathogens.
摘要:
Esta tecnología comprende compuestos derivados de 1, 3, 4-tiadiazol alquilamidas y de chalcona, los cuales inhiben la activación del receptor TRPV-1 por capsaicina y temperatura. Estos compuestos presentan una potente actividad antagonista para el modo de activación del receptor TRPV-1 por capsaicina y por temperatura. También se divulga el uso de estos compuestos en el tratamiento de enfermedades en las que el receptor TRPV-1 se encuentra sobreactivado, como por ejemplo el dolor crónico.